KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Net Cash Flow for 9 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 1223.3% year-over-year to $1.4 billion, compared with a TTM value of $235.0 million through Dec 2025, down 5.24%, and an annual FY2025 reading of $235.0 million, down 5.24% over the prior year.
  • Net Cash Flow was $1.4 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $51.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.4 billion in Q4 2025 and bottomed at -$1.6 billion in Q1 2025.
  • Average Net Cash Flow over 5 years is $90.8 million, with a median of $108.5 million recorded in 2022.
  • The sharpest move saw Net Cash Flow skyrocketed 1731.43% in 2023, then crashed 1158.02% in 2025.
  • Year by year, Net Cash Flow stood at $201.0 million in 2021, then soared by 113.93% to $430.0 million in 2022, then surged by 111.4% to $909.0 million in 2023, then tumbled by 88.67% to $103.0 million in 2024, then soared by 1223.3% to $1.4 billion in 2025.
  • Business Quant data shows Net Cash Flow for TEVA at $1.4 billion in Q4 2025, $51.0 million in Q3 2025, and $469.0 million in Q2 2025.